

GAU-1642  
#7 Day


PATENT

Docket No.: 176/60192 (6-11405-675/676)

7/1/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rosenblatt et al. )  
Serial No. : 09/016,743 )  
Filed : January 30, 1998 )  
For : CHIMERIC ANTIBODY FUSION PROTEINS )  
FOR THE RECRUITMENT AND )  
STIMULATION OF AN ANTITUMOR )  
IMMUNE RESPONSE )



Examiner:  
Y. Eyler

Art Unit:  
1642

RECEIVED

JUL 1 2 1999

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231


Box:

Dear Sir:

In response to the June 4, 1999, written restriction requirement, applicants hereby elect the invention of Group I (claims 1-10 and 25), with traverse. Applicants submit that all groups of invention identified in the written restriction requirement are closely related and, therefore, would require common areas of search and consideration. As a result, no benefit is derived from maintaining a restriction requirement, and withdrawal of that restriction requirement is respectfully requested.

Respectfully submitted,

Date: 7/1/99

  
Dennis M. Connolly  
Registration No. 40,964

Nixon Peabody LLP  
Clinton Square, P.O. Box 1051  
Rochester, New York 14603  
Telephone: (716) 263-1741  
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.

7/1/99. Richard Smith